Qiagen seeks judgment in COVID-19 wastewater testing suit
Qiagen has asked a Delaware court to issue a declaratory judgment that its method for testing for COVID-19 in wastewater does not infringe Bio-Rad’s patents.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
31 August 2021 A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
9 November 2021 Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents.
31 August 2021 A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
9 November 2021 Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents.
31 August 2021 A US District Court for the District of Delaware jury found that German genetics company Qiagen willfully infringed two patents owned by ArcherDX and Massachusetts General Hospital.
9 November 2021 Qiagen will pay Becton, Dickinson $53 million to settle an ongoing patent infringement lawsuit over polymerase chain reaction diagnostics patents.
